ACCELERON PHARMA INC. (NASDAQ:XLRN) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.
press release announcing its financial results for the fiscal
quarter ended March 31, 2017. A copy of the press release is
furnished as Exhibit 99.1 hereto.
attached hereto, is being furnished and shall not be deemed filed
for any purpose, and shall not be deemed incorporated by
reference in any filing under the Securities Act of 1933, as
amended, or the Securities Exchange Act of 1934, as amended,
regardless of any general incorporation language in any such
filing.
|
Exhibit Number
|
Description of Exhibit
|
|
|
99.1
|
Press release of Acceleron Pharma Inc. dated May 8,
2017 |
About ACCELERON PHARMA INC. (NASDAQ:XLRN)
Acceleron Pharma Inc. is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the discovery, development and commercialization of therapeutic candidates that are based on mechanisms, which the human body uses to regulate the growth and repair of its cells and tissues. Its therapeutic candidates are used to treat serious and rare diseases. The Company’s pipeline includes Luspatercept, Sotatercept, Dalantercept, ACE-083, ACE-2494, ACE-1332, ACE-3891, ACE-2798, ACE-2536 and ACE-2395. Luspatercept promotes red blood cell production. It is developing Sotatercept for the treatment of chronic kidney disease. Dalantercept treats cancers by inhibiting blood vessel formation by inhibiting signaling through the activin receptor-like kinase (ALK) 1 receptor. ACE-083 is for the treatment of focal muscle disorders. ACE-2494 is designed to treat systemic muscle disorders. ACE-3891, ACE-1332, ACE-2798, ACE-2536 and ACE-2395 are in preclinical stage of development. ACCELERON PHARMA INC. (NASDAQ:XLRN) Recent Trading Information
ACCELERON PHARMA INC. (NASDAQ:XLRN) closed its last trading session down -0.18 at 31.66 with 255,018 shares trading hands.
